Results 31 to 40 of about 18,378,232 (237)

Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? [PDF]

open access: yes, 2022
Clinical and experimental advances related to the detection, magnitude and pathobiology of subclinical portal hypertension in non-alcoholic fatty liver disease (NAFLD), primarily observed in the presence of non-alcoholic steatohepatitis (NASH), prompt us
Baffy, Gyorgy, Bosch, Jaime
core   +1 more source

ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver

open access: yesHepatology, EarlyView., 2022
Hepatic endothelial Alk1 signaling protects from development of vascular malformations while maintaining organ‐specific endothelial differentiation and angiocrine portmanteau of the names Wingless and Int‐1 signaling. Abstract Background and Aims In hereditary hemorrhagic telangiectasia (HHT), severe liver vascular malformations are associated with ...
Christian David Schmid   +20 more
wiley   +1 more source

Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS

open access: yesHepatology, EarlyView., 2022
The river diagram demonstrates that after transjugular intrahepatic portosystemic shunt insertion (TIPS) the majority of patients without ascites and 50% of the patients with ascites detectable at ultrasound, show the best response in the long term follow‐up.
Alexander Queck   +14 more
wiley   +1 more source

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

open access: yesHepatology, EarlyView., 2022
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan   +19 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

open access: yesHepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres   +21 more
wiley   +1 more source

Predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis [PDF]

open access: yesPeerJ, 2023
Objective This study aimed to explore the predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis. Methods From January 2017 to
Peng Wang, Xinhong Hu, Feng Xie
doaj   +2 more sources

Liver and Spleen Stiffness to Predict Portal Hypertension and Its Complications [PDF]

open access: yes, 2020
Portal hypertension is a common syndrome characterized by an increase in portal venous pressure driving life-threatening complications. In advanced chronic liver disease, increased portal venous pressure is one of the hallmarks of progression; in this ...
Berzigotti, Annalisa   +4 more
core   +1 more source

Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study

open access: yesHepatology, EarlyView., 2022
Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study. Abstract Background and Aims Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking.
Shannon M. Vandriel   +93 more
wiley   +1 more source

P-7 CLINICAL AND HISTOPATHOLOGICAL FEATURES OF THIRTY-FIVE OBLITERATIVE PORTAL VENOPATHY PATIENTS AND POTENTIAL ROLE OF XENOBIOTICS

open access: yesAnnals of Hepatology, 2021
Introduction: Classically described in the group of non-cirrhotic portal hypertension, Obliterative Portal Venopathy (OPV) is a spectral disease, which can be diagnosed before the manifestations of portal hypertension.
Vinicius Santos Nunes   +4 more
doaj   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

open access: yesHepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy